Phase II study of nimotuzumab combination with paclitaxel and cisplatin as the first-line treatment in patients with local advanced or metastatic esophageal squamous cell cancer (ESCC): An interim analysis

被引：0
|
作者：
Zhang, Xiaodong
Lu, Ming
Gong, Jifang
Gao, Jing
Wang, Xicheng
Zhang, Xiaotian
Li, Jie
Li, Yan
Li, Jian
Zhou, Jun
Lu, Zhihao
Shen, Lin
机构：
[1] Peking Univ, Sch Oncol, Dept Gastrointestinal Oncol, Beijing 100871, Peoples R China
[2] Beijing Canc Hosp & Inst, Beijing, Peoples R China
[3] Peking Univ, Canc Hosp, Beijing 100871, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14604
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Nimotuzumab plus paclitaxel and cisplatin as first-line treatment for esophageal squamous cell cancer: Final results of a single-center prospective clinical trial.
    Lu, Ming
    Wang, Xicheng
    Lu, Zhihao
    Li, Jian
    Li, Jie
    Li, Yan
    Zhang, Xiaotian
    Zhou, Jun
    Gong, Jifang
    Jia, Jun
    Yu, Jing
    Cui, Yan
    Shen, Lin
    Zhang, Xiaodong
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [32] Phase II study of S-1 in combination with paclitaxel as a first-line treatment for patients with advanced/recurrent gastric cancer
    Toh, U.
    Yamana, H.
    Koufuji, K.
    Mine, T.
    Aoyagi, K.
    Miyagi, M.
    Imaizumi, T.
    Shirouzu, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [33] A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer
    Kang, H. J.
    Chang, H. M.
    Kim, T. W.
    Ryu, M-H
    Sohn, H-J
    Yook, J. H.
    Oh, S. T.
    Kim, B. S.
    Lee, J-S
    Kang, Y-K
    BRITISH JOURNAL OF CANCER, 2008, 98 (02) : 316 - 322
  • [34] A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer
    H J Kang
    H M Chang
    T W Kim
    M-H Ryu
    H-J Sohn
    J H Yook
    S T Oh
    B S Kim
    J-S Lee
    Y-K Kang
    British Journal of Cancer, 2008, 98 : 316 - 322
  • [35] Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for advanced esophageal squamous cell carcinoma (ESCC): A multicenter, single-arm, open-label phase II clinical trial.
    Wang Junsheng
    Luo Suxia
    Li Ning
    Wu Tao
    Hong Yonggui
    Guo Yanzhen
    Cheng Yufeng
    Li Baosheng
    Tan Bingxu
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [36] A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer
    Cejalvo, Juan-Miguel
    Jacob, Wolfgang
    Kanonnikoff, Tania Fleitas
    Felip, Enriqueta
    Navarro Mendivil, Alejandro
    Martinez Garcia, Maria
    Garcia, Alvaro Taus
    Leighl, Natasha
    Lassen, Ulrik
    Mau-Soerensen, Morten
    Adessi, Celine
    Michielin, Francesca
    James, Ian
    Ceppi, Maurizio
    Hasmann, Max
    Weisser, Martin
    Cervantes, Andres
    ESMO OPEN, 2019, 4 (04)
  • [37] Phase II trial of paclitaxel and cisplatin combination given biweekly as first-line chemotherapy in patients with advanced or metastatic squamous cell carcinoma of esophagus from a single center in China.
    Zhou, Y.
    Huang, J.
    Yang, L.
    Cai, G. R.
    Xu, H. B.
    Wang, W. J.
    Shi, K. Y.
    Sun, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [38] A phase II study of paclitaxel and bevacizumab ± gemcitabine as first-line treatment for metastatic breast cancer (MBC): Interim safety results
    Brufsky, A. M.
    Hoelzer, K. L.
    Keaton, M. R.
    Beck, J. T.
    Krill-Jackson, E.
    Wang, Y.
    Hu, S.
    Vaughn, L. G.
    Shonukan, O. O.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [39] Phase II study of nedaplatin and amrubicin as first-line treatment for advanced squamous cell lung cancer
    Taniguchi, Hirokazu
    Yamaguchi, Hiroyuki
    Dotsu, Yosuke
    Shimada, Midori
    Gyotoku, Hiroshi
    Senju, Hiroaki
    Takemoto, Shinnosuke
    Kitazaki, Takeshi
    Fukuda, Masaaki
    Ogawara, Daiki
    Soda, Hiroshi
    Nakatomi, Katsumi
    Sugasaki, Nanae
    Kinoshita, Akitoshi
    Nagashima, Seiji
    Ikeda, Takaya
    Nakamura, Yoichi
    Sakamoto, Noriho
    Obase, Yasushi
    Fukuda, Minoru
    Mukae, Hiroshi
    THORACIC CANCER, 2019, 10 (09) : 1764 - 1769
  • [40] Randomized multicenter phase II study with docetaxel in combination with either cisplatin or oxaliplatin as first-line treatment in patients with advanced or metastatic non-small cell lung cancer
    Atmaca, A.
    Al-Batran, S.
    Guener, T.
    Pauligk, C.
    Koepke, A.
    Bernhard, H.
    Wenzel, T.
    Banat, A. G.
    Brueck, P.
    Caca, K.
    Prasnikar, N.
    Kullmann, F.
    Jaeger, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345